Be Clinical Raises INR 6 Crore in Seed Funding Led by Arjun Vaidya’s V3 Ventures; Backed by Kunal Bahl and Rohit Bansal of Titan Capital

Be Clinical, an evidence-led skincare brand focused on clinically effective solutions for ageing skin, has raised INR 6 crore in seed funding. The round was led by V3 Ventures, with participation from Titan Capital, founded by Kunal Bahl and Rohit Bansal, who have doubled down on their commitment to the brand.

Founded by Hemangi Dhir, Be Clinical was created to address a clear gap in the Indian skincare market, the lack of science-led, transparent, and clinically validated solutions designed specifically for Indian skin and environmental conditions. While much of the category is driven by marketing claims or inaccessible clinical treatments, Be Clinical differentiates itself through in-vivo tested, clinically validated formulations, supported by end-to-end in-house research and manufacturing and responsible formulation.

The seed capital will be strategically deployed across three core areas. A significant portion will be invested in research and development to strengthen in-house formulation capabilities, conduct clinical testing, and develop targeted solutions for ageing concerns across the face, body, and scalp. The company will also expand its manufacturing facility by adding advanced machinery to improve production capacity, consistency, and quality control. In addition, part of the funding will be used to upgrade packaging with functional, protective, and premium formats that preserve ingredient efficacy while reinforcing the brand’s clinical-grade positioning.

Commenting on the fundraise, Hemangi Dhir, Founder, Be Clinical, said, “This moment feels incredibly special for us. The continued support from our existing investors, along with the partnership with V3 Ventures and Titan Capital, gives us strong conviction as we enter our next phase of growth. At Be Clinical, we are deeply committed to honest skincare — where evidence leads, trust is earned, and ageing is addressed with clarity, confidence, and care.”

Arjun Vaidya, Co-Founder at V3 Ventures said, “At V3, we are seeing a big change in the beauty and personal care space. Customers have moved from being generalists to knowledgeable and specific. We believe anti-aging is a massive, untapped space that starts seeing relevance in a consumer's mind mid 20s. We loved Hemangi's vision, depth of product knowledge and in-house manufacturing prowess. This is what drew us to back the venture early and we are really excited for what's ahead.”

Building on their early backing, the investor once again expressed conviction in the company’s journey.

"We are happy to back Be Clinical again. We backed Hemangi because she is solving a real problem with a product-led, science-driven approach. The company has stayed focused on building formulations that work, not on chasing trends. As the company scales, that clarity of thinking and discipline around the product is what gives us confidence in their long-term potential”, said a spokesperson at Titan Capital.

Launched in May 2025, Be Clinical has demonstrated strong early traction in a short period. As of December 31, 2025, the brand has served over 25,000 customers, reflecting rapid adoption and growing consumer trust in its clinically driven, India-specific skincare solutions. This early momentum underscores a clear market demand for science-backed formulations that prioritise efficacy, transparency, and education over trend-based claims.